The low-risk group had higher mutation frequency of IDH1, TP53, ATRX, and CIC, in contrast to the high-risk group that had higher mutation frequency of PTEN, EGFR, MUC16, and PIK3CA. The somatic mutation results were consistent with the existing researches about prognosis of the gliomas (Rasheed et al., 1997; Cancer Genome Atlas Research et al., 2015; Chen et al., 2019; Bjorkblom et al., 2022; Ferrer, 2023). The gene discussed is ATRX; the disease is central nervous system cancer.